Citius Oncology, Inc. CTOR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Citius Oncology, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s return on equity?
- Citius Oncology, Inc. (CTOR) reported return on equity of -119.9% in Q1 2026.
- How has Citius Oncology, Inc.'s return on equity changed year-over-year?
- Citius Oncology, Inc.'s return on equity decreased by 28.0% year-over-year, from -93.6% to -119.9%.
- What is the long-term trend for Citius Oncology, Inc.'s return on equity?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s return on equity has grown at a 15.1% compound annual growth rate (CAGR), from -41.1% to -54.4%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.